Actively Recruiting
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Led by M.D. Anderson Cancer Center · Updated on 2025-11-25
775
Participants Needed
10
Research Sites
325 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.
CONDITIONS
Official Title
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must sign informed consent and authorization for release of protected health information.
- Participants must be between 30 and 84 years old.
- Participants must have one of the following diagnoses based on study definitions:
- New onset diabetes (<3 years) with pancreatic cancer.
- New onset diabetes (<3 years) with chronic pancreatitis.
- New onset diabetes (<3 years) without pancreatic disease (type 2 diabetes).
- Long-standing type 2 diabetes (≥3 years) without pancreatic disease.
- Long-standing diabetes (≥3 years) with pancreatic cancer.
- Long-standing diabetes (≥3 years) with chronic pancreatitis.
- Non-diabetic participants with pancreatic cancer.
- Non-diabetic participants with chronic pancreatitis.
- Non-diabetic controls without pancreatic disease.
You will not qualify if you...
- Participants with significant uncontrolled medical illnesses that would compromise study participation.
- Diabetes not stable enough to allow holding diabetes medications during mixed meal testing.
- Participants taking insulin doses of 0.75 unit/kg/day or higher (except pancreatic cancer participants undergoing fasting only blood collection).
- Participants without pancreatic disease using longer-acting agents such as thiazolidinediones or once-weekly GLP-1 agonists (not applicable for chronic pancreatitis or pancreatic cancer groups).
- Participants currently on oral steroid medications.
- Hospitalization for acute pancreatitis within 2 months before study visit (not applicable for pancreatic cancer participants undergoing fasting only blood collection).
- Presence of symptomatic cysts in chronic pancreatitis participants (not applicable for pancreatic cancer participants undergoing fasting only blood collection).
- Participants with pancreatic cancer histologic types other than adenocarcinoma.
- Previous pancreatic surgery (except certain surgeries allowed in chronic pancreatitis participants with diabetes).
- Previous treatment for pancreatic cancer including chemotherapy or radiation.
- Previous vagotomy or gastric surgery including endoscopic gastric reduction (not applicable for pancreatic cancer participants undergoing fasting only blood collection).
- Previous diagnosis of gastroparesis (not applicable for pancreatic cancer participants undergoing fasting only blood collection).
- Participants treated for any cancer except non-melanoma skin cancer or carcinoma in-situ of the cervix.
- Allergy or intolerance to ingredients in the Boost drink for participants undergoing mixed meal testing (not applicable for pancreatic cancer participants undergoing fasting only blood collection).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Active, Not Recruiting
2
Stanford University
Stanford, California, United States, 94305
Active, Not Recruiting
3
University of Florida
Gainesville, Florida, United States, 32610
Active, Not Recruiting
4
Indiana University
Carmel, Indiana, United States, 46280
Active, Not Recruiting
5
University of Minnesota
Minneapolis, Minnesota, United States, 55454
Active, Not Recruiting
6
Mayo Clinic
Rochester, Minnesota, United States, 55905
Active, Not Recruiting
7
Ohio State University
Columbus, Ohio, United States, 43210
Active, Not Recruiting
8
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Active, Not Recruiting
9
Baylor College of Medicine
Houston, Texas, United States, 77030
Active, Not Recruiting
10
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
Y
Ying Yuan, PHD
CONTACT
S
Suresh Chari, MBBS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here